Updated: Dec 16, 2021
Bent Jakobsen, who has previously co-founded three biotech companies abroad, is now helping to establish his fourth of its kind, Synaptixbio, which will tackle one of the world's rarest neurological disorders.
To continue reading please go to the article on MedWatch
Dr Dan Williams, CEO and Co-Founder of new biotech business SynaptixBio, discusses how the search is on to find the first treatment for one of the world’s rarest diseases, TUBB4A-associated leukodystr
SynaptixBio, an Oxford, UK-based research company, has been launched by a worldwide team of medical and pharmaceutical scientists to develop the world’s first disease modifying treatment for leukodyst
A new biotech business SynaptixBio has been launched to tackle one of the world’s rarest neurodegenerative diseases. SynaptixBio is working to develop the world’s first disease-modifying treatment for
